InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences

Rhea-AI Summary

InflaRx (Nasdaq: IFRX), a biopharmaceutical company developing anti-inflammatory therapeutics targeting the complement system, will release its fourth quarter and full year 2024 financial results on March 20, 2025, without a conference call.

The company will participate in two upcoming investor conferences: the Leerink Global Healthcare Conference (March 9-12 in Miami Beach) featuring a fireside chat on March 10 at 10:40 AM ET, and the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference on March 27, with a virtual fireside chat at 8:30 AM ET. Both events will include one-on-one investor meetings.

InflaRx specializes in developing inhibitors of the complement activation factor C5a and its receptor C5aR. Their lead product candidate is vilobelimab, an intravenous anti-C5a monoclonal antibody, and they're also developing INF904, an oral C5a receptor inhibitor.

JENA, Germany, Feb. 25, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will publish its financial and operating results for the fourth quarter and full year 2024 on March 20, 2025; no conference call is planned.

InflaRx also announced that it will participate in two investor conferences. Details are as follows:

Leerink Global Healthcare Conference
March 9 - 12, 2025 in Miami Beach, FL

InflaRx will conduct a fireside chat at the conference on March 10 at 10:40 AM ET and will participate in one-on-one-investor meetings. A link to register for the fireside chat live stream and its replay is available here.

H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
March 27, 2025

InflaRx will conduct a virtual fireside chat on March 27 at 8:30 AM ET and will participate in one-on-one-investor meetings. A link to register for the fireside chat live stream and its replay is available here.

About InflaRx
InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx’s lead product candidate, vilobelimab, is a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies in different indications. InflaRx is also developing INF904, an orally administered, small molecule inhibitor of the C5a receptor. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.com.

InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx).

Contacts:

InflaRx N.V.	MC Services AG
Jan Medina, CFA Vice President, Head of Investor Relations Email: IR@inflarx.de	Katja Arnold, Laurie Doyle, Dr. Regina Lutz Email: inflarx@mc-services.eu Europe: +49 89-210 2280 U.S.: +1-339-832-0752

FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue,” among others. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations and the risks, uncertainties and other factors described under the headings, “Risk factors” and “Cautionary statement regarding forward looking statements”, in our periodic filings with the SEC. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

FAQ

When will InflaRx (IFRX) release its full year 2024 financial results?

InflaRx will publish its fourth quarter and full year 2024 financial and operating results on March 20, 2025. No conference call is planned for this announcement.

Which investor conferences will InflaRx (IFRX) attend in March 2025?

InflaRx will participate in the Leerink Global Healthcare Conference (March 9-12 in Miami Beach) and the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference (March 27, 2025).

What is InflaRx's (IFRX) lead product candidate?

InflaRx's lead product candidate is vilobelimab, a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that has demonstrated disease-modifying clinical activity in multiple studies.

What therapeutic area does InflaRx (IFRX) focus on?

InflaRx focuses on pioneering anti-inflammatory therapeutics by targeting the complement system, specifically developing inhibitors of the complement activation factor C5a and its receptor C5aR.

What products are in InflaRx's (IFRX) development pipeline?

InflaRx is developing vilobelimab, an intravenous anti-C5a monoclonal antibody, and INF904, an orally administered small molecule inhibitor of the C5a receptor.